![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
EU WC
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
85
PharmaCompass offers a list of Epoprostenol Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Epoprostenol Sodium manufacturer or Epoprostenol Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Epoprostenol Sodium manufacturer or Epoprostenol Sodium supplier.
PharmaCompass also assists you with knowing the Epoprostenol Sodium API Price utilized in the formulation of products. Epoprostenol Sodium API Price is not always fixed or binding as the Epoprostenol Sodium Price is obtained through a variety of data sources. The Epoprostenol Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Epoprostenol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Epoprostenol, including repackagers and relabelers. The FDA regulates Epoprostenol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Epoprostenol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Epoprostenol manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Epoprostenol supplier is an individual or a company that provides Epoprostenol active pharmaceutical ingredient (API) or Epoprostenol finished formulations upon request. The Epoprostenol suppliers may include Epoprostenol API manufacturers, exporters, distributors and traders.
click here to find a list of Epoprostenol suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Epoprostenol DMF (Drug Master File) is a document detailing the whole manufacturing process of Epoprostenol active pharmaceutical ingredient (API) in detail. Different forms of Epoprostenol DMFs exist exist since differing nations have different regulations, such as Epoprostenol USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Epoprostenol DMF submitted to regulatory agencies in the US is known as a USDMF. Epoprostenol USDMF includes data on Epoprostenol's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Epoprostenol USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Epoprostenol suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Epoprostenol Drug Master File in Japan (Epoprostenol JDMF) empowers Epoprostenol API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Epoprostenol JDMF during the approval evaluation for pharmaceutical products. At the time of Epoprostenol JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Epoprostenol suppliers with JDMF on PharmaCompass.
A Epoprostenol written confirmation (Epoprostenol WC) is an official document issued by a regulatory agency to a Epoprostenol manufacturer, verifying that the manufacturing facility of a Epoprostenol active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Epoprostenol APIs or Epoprostenol finished pharmaceutical products to another nation, regulatory agencies frequently require a Epoprostenol WC (written confirmation) as part of the regulatory process.
click here to find a list of Epoprostenol suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Epoprostenol as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Epoprostenol API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Epoprostenol as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Epoprostenol and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Epoprostenol NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Epoprostenol suppliers with NDC on PharmaCompass.
Epoprostenol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Epoprostenol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Epoprostenol GMP manufacturer or Epoprostenol GMP API supplier for your needs.
A Epoprostenol CoA (Certificate of Analysis) is a formal document that attests to Epoprostenol's compliance with Epoprostenol specifications and serves as a tool for batch-level quality control.
Epoprostenol CoA mostly includes findings from lab analyses of a specific batch. For each Epoprostenol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Epoprostenol may be tested according to a variety of international standards, such as European Pharmacopoeia (Epoprostenol EP), Epoprostenol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Epoprostenol USP).